Medical Oncologist and PhD candidate. Affiliated with Wollongong Hospital, and University of Sydney, 🇦🇺. Views my own.
Sydney, New South Wales
Joined March 2012
- Tweets344
- Following315
- Followers299
- Likes553
Great to be a part of the AC2 leaders forum in Hong Kong, working towards further collaborations in #CancerSurvivorship care for Chinese speaking populations #survonc @janette_vardy @drcarolynee @chitchadkitchen @rayychan
This forum will drive pivotal conversations about improving cancer survivorship care for people with a Chinese background, through innovation and cross-cultural understanding. Special thanks to HKU for hosting and NFACR for their support! #AC2Forum #CancerSurvivorship
Congratulations to this wonderful team 🎉 @IllaShoalHealth
Congratulations to Wollongong Hospital – 2023 Outstanding Cancer Clinical Trials Unit. #cancerNSWawards
🚨Glad to share my first PhD 📝 Addressing barriers to care in cancer survivors from #CALD backgrounds is an unmet need! Results from existing #survivorship intervention studies are promising but more work is needed, particularly in non-breast cancer survivors #survonc
Cancer survivorship programs for patients from culturally and linguistically diverse (CALD) backgrounds: a scoping review | SpringerLink link.springer.com/article/10…
Uterine cancer is a devastating disease where improvements in treatment are continuously needed, especially for those with metastatic disease. Grateful for the opportunities to work with @anzgog to increase awareness and improve outcomes for those affected #gyncsm – at Sydney, New South Wales
Great story from @BecPridham
Uterine and other gynaecological cancers on the rise but many women in the dark, expert says abc.net.au/news/2023-07-22/u… via @ABCaustralia Am working hard to lead the EDEN initiative to make progress in this space with a new group and new trials @anzgog
"Traditional" medicines are being used whether clinicians recommend or discourage their use - it's up to us as clinician researchers to advocate for more #clinicaltrials to expand the evidence base to better inform our patients #EBM #MASCC23 @CancerCareMASCC @coffeemommy – at Nara-shi, Nara
Thank you @CancerCareMASCC for allowing me to present my scoping review focused on #cancersurvivorship programs in #CALD cancer survivors. Lots of work to be done! 📝 out soon @janette_vardy @CindyTa09878114 @AshMalalasekera @Joanne472 @Sydney_Uni #survonc – at Nara-shi, Nara
Glad to share our review 📝 by Won-Hee Yoon and @annapoids on #immunotherapy in #ovariancancer and where we are headed #gyncsm #ocsm @anzgog
#Ovariancancer #immunotherapy #tumourmicroenvironment
Welcome to read
🌈Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
👉f.oaes.cc/xmlpdf/a1aa8691-49…
@KDRichardson924 @sundar_sudha @SwisherLab @WIOvarianCancer @OCNA @SherryPollex
So so great to finally meet you @AshMalalasekera! Next mission is to meet @Joanne472... #PhDSupervisors #gottameetthemall #ANZGOGASM2023
When you bump into your PhD student (and his partner) for the first time ever in person! 1.5 years into PhD 😊😊 Lovely to have a real catch-up with @LKasherman #TallerInPerson #WhoDis #ANZGOGASM2023
1
17
793
✨🙌✨ @AinhoaMada well done!
Great satelite session by @AinhoaMada Where are we going with EC? Aiming to improve outcomes in primary advanced or recurrent endometrial cancer with PD-(L)1 inhibitors
1
10
738
Excited to give patients affected by gynaecologic cancers an opportunity to participate in @anzgog clinical trials locally #gyncsm @IllaShoalHealth
TRIAL SITE ACTIVATION 🏥🚨
Wollongong Hospital is recruiting for PARAGON-II. The trial is now open at 10/16 hospitals across Australia & New Zealand.
@TrialsCentre @LKasherman
Find out more:
anzgog.org.au/trials
Very grateful to @nhmrc for supporting my #PhD research into improving outcomes for cancer survivors of #CALD backgrounds! @janette_vardy @CindyTa09878114 @Joanne472 @AshMalalasekera
Congratulations to SCP PhD students Ellie Medcalf and @LKasherman, outstanding #NHMRC scholars! Ellie is investigating new epidemiological methods in the MEL-SELF CT and Lawrence is aiming to improve outcomes & experiences of CALD cancer patients in survivorship programs. 👏👏
Thanks to @SydCancerPtnrs for awarding me with this opportunity! Also couldn’t have done it without ✨stellar✨ supervision from @janette_vardy @Joanne472 @AshMalalasekera @CindyTa09878114
👏👏Huge congratulations to our new PhD Scholarship recipients. Welcome to the team. We are proud to be supporting the next generation of #CancerResearch stars ⭐️⭐️. @cancerNSW @syd_health @SydCancerNetwrk
Headlines like these are thoroughly problematic on many levels - as much as oncologists want to be excited about breakthrough trial results, we always look at the fine details to make sure we are recommending the right treatments, instead of creating false hope and disappointment
Why?! No wonder cancer patients and their loved ones feel confused!
Another day of damage control with patients who are worried they are missing out!! 😡
5
Finally!!
PSMA PET/CT (Ga-68 and F-18) will be reimbursed in Australia from 01 Jul 22 for staging intermediate-to-high risk and biochemical recurrence. Direct result of Australian led research @PeterMacCC @ANZUPtrials #ARTnet
Stop the defunding of specialist telehealth for rural, aged care and indigenous patients - Sign the Petition! chng.it/JFSjTDKb via @ChangeAUS
Using @Spotify to nerd out this year… thanks @IJGConline for keeping me company on my long work commutes! #wrapped2021
1
1
Trainee mental health needs to be talked about.
Trainees don’t need fruit bowls, fit-bits, yoga classes or resilience training. Trainees need to stop being exploited as cheaper-than-consultant service provision under the guise of “training” and staffing needs to have redundancy to allow cover for leave. smh.com.au/national/nsw/dist…
7
Glad to see this trial finally presented with positive results! #gyncsm
PRACTICE CHANGE at #ESMO21 - KEYNOTE-826 - the addition of pembroliuzumab #Immunotherapy to standard of care chemotherapy/bevacizumab demonstrates improved progression free and overall survival in advanced/recurrent #CervicalCancer. Regardless of PDL1 status or bev use #gyncsm
